<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Biochem Nutr</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Biochem Nutr</journal-id><journal-id journal-id-type="publisher-id">JCBN</journal-id><journal-title-group><journal-title>Journal of Clinical Biochemistry and Nutrition</journal-title></journal-title-group><issn pub-type="ppub">0912-0009</issn><issn pub-type="epub">1880-5086</issn><publisher><publisher-name>the Society for Free Radical Research Japan</publisher-name><publisher-loc>Kyoto, Japan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22798707</article-id><article-id pub-id-type="pmc">3391858</article-id><article-id pub-id-type="publisher-id">jcbn11-87</article-id><article-id pub-id-type="doi">10.3164/jcbn.11-87</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of rice bran oil on the blood lipids profiles and insulin resistance in type 2 diabetes patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lai</surname><given-names>Ming-Hoang</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yi-Ting</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ya-Yen</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Jui-Hung</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Hsing-Hsien</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Nursing, Cardinal Tien College of Healthcare and Management, Sindian District, New Taipei City, 23143, Taiwan</aff><aff id="aff2"><label>2</label>School of Nutrition and Health Sciences, Taipei Medical University, Taipei, Taiwan</aff><aff id="aff3"><label>3</label>Department of Nursing, Chang Gung Institute of Technology, Taoyuan, Taiwan</aff><author-notes><corresp id="cor1">*To whom correspondence should be addressed. E-mail: <email>yayen0220@yahoo.com.tw</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>13</day><month>12</month><year>2011</year></pub-date><volume>51</volume><issue>1</issue><fpage>15</fpage><lpage>18</lpage><history><date date-type="received"><day>7</day><month>7</month><year>2011</year></date><date date-type="accepted"><day>1</day><month>8</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 JCBN</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The aim of this study was to investigate the influence of rice bran oil consumption on plasma lipids and insulin resistance in patients with type 2 diabetes. Thirty-five patients with type 2 diabetes were randomly assigned to a placebo group or a rice bran oil group. The placebo group consumed 250&#x000a0;mL soybean oil-modified milk (18&#x000a0;g soybean oil) daily for 5 weeks, and the rice bran oil group consumed 250&#x000a0;mL rice bran oil modified milk (18&#x000a0;g rice bran oil) daily for 5 weeks. At week 0 and week 5, anthropometric measurements, hematology tests, and an oral-glucose-tolerance test were conducted. The results showed that the homeostasis model assessment index of insulin resistance, the area under the curve for postprandial serum insulin, and serum low-density-lipoprotein cholesterol concentrations increased significantly in the placebo group. In the rice bran oil group, fasting and 2-h postprandial blood glucose concentrations and the area under the curve for postprandial plasma glucose increased significantly; however, total serum cholesterol and low-density-lipoprotein cholesterol concentrations decreased significantly. However, the homeostasis model assessment index of insulin resistance was not significantly different. Consumption of 18&#x000a0;g rice bran oil modified milk daily for 5 weeks significantly decreased total serum cholesterol concentrations and tended to decrease low-density-lipoprotein cholesterol concentrations in patients with type 2 diabetes. However, no significant influence on insulin resistance was observed.</p></abstract><kwd-group><kwd>rice bran oil</kwd><kwd>type 2 diabetes</kwd><kwd>blood lipids</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The World Health Organization reported that 50&#x02013;80% of patients with type 2 diabetes die from cardiovascular diseases. In diabetes mellitus complicated by cardiovascular disease, insulin resistance and abnormal blood lipid concentrations play an important role.<sup>(<xref ref-type="bibr" rid="B1">1</xref>)</sup> Dietary oil intake has an important influence on blood lipid concentrations.<sup>(<xref ref-type="bibr" rid="B2">2</xref>)</sup> In 1980, researchers found that both the quantity and quality of dietary oil are associated with lipid metabolic disorders. Different compositions of fatty acids have different influences on lipid metabolic disorder.<sup>(<xref ref-type="bibr" rid="B3">3</xref>)</sup></p><p>In Asia, rice bran oil (RBO) consumption has increased year by year.<sup>(<xref ref-type="bibr" rid="B4">4</xref>)</sup> Researchers have reported that oleic acid is the predominant fatty acid (38.4%) in RBO.<sup>(<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>)</sup> In a streptozotocin-induced diabetic rat model, plasma and liver triglyceride (TG) concentrations and insulin resistance decreased significantly and fecal neutral sterol concentrations and bile acid excretion increased after 4 wk of feeding with 15% RBO.<sup>(<xref ref-type="bibr" rid="B6">6</xref>)</sup> Total serum cholesterol concentrations decreased significantly in healthy subjects who consumed 75&#x000a0;mL RBO daily for 50 d.<sup>(<xref ref-type="bibr" rid="B7">7</xref>)</sup> Also, the use of RBO as a cooking oil can significantly decrease plasma TC and TG concentrations in hyperlipidemic patients.<sup>(<xref ref-type="bibr" rid="B8">8</xref>)</sup> However, the effect of RBO consumption on patients with type 2 diabetes remains unclear. Therefore, the aim of this study was to investigate the effect of RBO consumption on plasma lipids and insulin resistance in patients with type 2 diabetes.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>A total of 40 patients with type 2 diabetes aged 30&#x02013;80 years old were recruited from the Endocrinology and Metabolism Departments of Taipei Medical University Hospital and of Lotung Poh-Ai Hospital. The study subjects had a fasting blood glucose concentration &#x02a7e;126&#x000a0;mg/dL and no acute complications. Cardiovascular disease, cerebrovascular disease, kidney disease, gastrointestinal disease, liver disease (hepatitis B &#x00026; C virus carrier, liver cirrhosis), thyroid disease, cancer, stroke, type 1 diabetes, and pregnancy were exclusion factors. This study was approved by the Human Experiment &#x00026; Ethics Committees of Taipei Medical University Hospital and Lotung Poh-Ai Hospital. Written inform consent was obtained from each subject. However, 2 subjects can not co-operate with our experimental time, severe hemolysis occurred on 3 subjects, so 35 DM patients completed the all experiment finally.</p><p>This was a randomized, single blind, placebo, comparison study. The subjects were randomly assigned to a placebo group or an RBO group. The placebo group consumed 250&#x000a0;mL soybean oil&#x02013;modified milk (18&#x000a0;g soybean oil) daily for 5 weeks, and the RBO group consumed 250&#x000a0;mL RBO-modified milk (18&#x000a0;g RBO) daily for 5 weeks. During the study period, breakfast was replaced with either the placebo or the RBO-modified milk; the reminder of the diet, lifestyle habits, and medication use were unchanged. At weeks 0 and 5, anthropometric measurements, hematology tests, and an oral-glucose-tolerance test (OGTT) were conducted. For the OGTT, fasting blood samples were collected and then the subjects ingested a 75-g glucose solution. Blood samples were then collected 30, 60, 90, 120, and 180&#x000a0;min after consumption of the glucose solution. During the study period, the subjects completed a diet diary 3 d/week, including 2 weekdays and 1 holiday. The modified milk (Tetra Pak; Jia Ge Food Co., Ltd.) contained 7.1&#x000a0;g sucrose, 11.6&#x000a0;g casein, and 18&#x000a0;g soybean oil (placebo group) or 18&#x000a0;g RBO (RBO group)&#x02014;12.0% sugar, 19.6% protein, and 68.4% lipid. The composition of fatty acids in the modified milk is shown in Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>.</p><p>The diet diaries were analyzed by using EK-NUTN8 to calculate the consumption of calories and the 3 major macronutrients. The blood samples were centrifuged at 3000&#x000a0;rpm for 10&#x000a0;min at &#x02a7d;4&#x000b0;C. The Glucose Kit (Randox Laboratories Ltd., Co. Antrim, UK) was used to measure plasma glucose concentrations. The Human Insulin ELISA Kit (Mercodia, Uppsala, Sweden) was used to measure serum insulin concentration. Insulin resistance was reported as the homeostasis model assessment of insulin resistance (HOMA-IR) index, and the formula used was as follows: fasting insulin (&#x000b5;U/mL)&#x000a0;&#x000d7;&#x000a0;glucose (mmol/L)/22.5.<sup>(<xref ref-type="bibr" rid="B9">9</xref>)</sup> High-performance liquid chromatography (HLC-723 V, Tosoh, San Francisco, CA) was used to measure glycated hemoglobin (Hb A<sub>1c</sub>). Serum TG, TC, high-density-lipoprotein cholesterol (HDL-C), and LDL-C concentrations were analyzed with kits from Beckman (Fullerton, California, United States). Gas chromatography was performed by using a G-3000 gas chromatograph, and an FID detector and D-2500 integrator (Hitachi, Ltd., Japan) were used to analyze the composition (%) of modified milk. The chromatography column used was a Restek capillary column (Stabilwax DA 30&#x000a0;m, 0.53&#x000a0;mm ID). The total fatty acid composition was quantified by using a methylation process.<sup>(<xref ref-type="bibr" rid="B7">7</xref>)</sup> The C17:0 fatty acid was used as an internal standard, and the types of fatty acid were determined according to hold time and expressed as a percentage (each fatty acid/total fatty acid).</p><sec><title>Statistical analysis</title><p>The data are presented as means&#x000a0;&#x000b1; SEMs. SAS 9.0 software (SAS Institute, Cary, NC) was used for the statistical analysis. Student&#x02019;s <italic>t</italic> test was used to compare baseline data between the placebo and RBO groups and to compare percentage changes before and after the study intervention. A paired <italic>t</italic> test was used to compare data from before and after the study intervention between the placebo group and the RBO group. <italic>p</italic>&#x0003c;0.05 indicated a statistical difference.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Two subjects did not meet the time requirement and 3 subjects had serious hemolysis; therefore, only 35 subjects completed the study. The average ages of the placebo group and the RBO group were 57.5 and 56.2 years, respectively. No significant differences in weight, BMI, or systolic and diastolic blood pressures were observed in a comparison of values before and after the study intervention (data not shown).</p><p>The results of the dietary analysis are shown in Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>. No significant differences in calorie intakes, macronutrient intakes, or macronutrient intakes as a percentage of calories were observed in a comparison of values before and after the study intervention between the 2 groups.</p><p>Blood biochemistry values are shown in Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>. In the RBO group, the fasting glucose concentration increased significantly by 6.5% after the study intervention. The 2-h postprandial blood glucose concentration increased significantly by 10.6%. In the placebo group, fasting and 2-h postprandial blood sugar concentrations did not change significantly after the study intervention. No significant differences in fasting serum insulin concentrations were found in a comparison of values before and after the study intervention in the placebo and RBO groups. In the RBO group, the HOMA-IR value increased by 20.7% after the study intervention, but the change was not significantly different. In the placebo group, the HOMA-IR value increased by 36.3% after the study intervention. No significant differences in Hb A<sub>1C</sub> were observed in a comparison of values before and after the study intervention in the placebo and RBO groups. In the RBO group, the serum TC concentration was significantly lower after the intervention than before the intervention. LDL-C decreased from 111.9&#x000a0;&#x000b1;&#x000a0;6.6 to 108.0&#x000a0;&#x000b1;&#x000a0;6.6&#x000a0;mg/dL and had the tendency of decreasing, but TG and HDL-C concentrations did not change significantly. However, LDL-C was significantly higher after the study intervention than before the intervention in the placebo group. No significant differences in TC, TG, or HDL-C concentrations were observed in a comparison of values before and after the study intervention in the placebo group. A comparison of the percentage change in TC before and after the study intervention showed a significant 1.6&#x000a0;&#x000b1;&#x000a0;1.6% increase in the placebo group but a 3.6&#x000a0;&#x000b1;&#x000a0;1.2% significant decrease in the RBO group. A comparison of the percentage change in LDL-C before and after the study intervention showed a significant 6.4&#x000a0;&#x000b1;&#x000a0;3.1% increase in the placebo group but a significant 2.7&#x000a0;&#x000b1;&#x000a0;3.1% decreased in the RBO group.</p><p>Results of the OGTT showed that the area under the curve (AUC) for postprandial plasma glucose, after the study intervention, was significantly higher than that before the intervention in the RBO group. However, no significant difference in the AUC of postprandial plasma glucose before and after the intervention was observed in the placebo group. In the placebo group, the AUC for postprandial serum insulin was higher after the study intervention than before the intervention. However, no significant difference in the AUC of postprandial serum insulin was found in a comparison of values before and after the study intervention in the RBO group<xref ref-type="fig" rid="F1"/><xref ref-type="fig" rid="F2"/>.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The aim of this study was to determine the effects of RBO on the blood lipids profiles and insulin resistance in type 2 diabetes patients. A significantly increasing of fasting and two hour postprandial blood glucose were observed in the RBO group compared to the placebo group. In addition, the total serum cholesterol and LDL-C concentration decreased significantly by 5-week dietary intervention involving consumption of RBO.</p><p>The reason why a significantly increasing of fasting and two hour postprandial blood glucose were observed in the RBO group compared to the placebo group could be associated with the AUC for insulin. In our study, we found the AUC for insulin at 5 week did not increase significantly than that at 0 week in RBO group. We supposed there could be two reasons resulted in this situation. First, according to our results, we found that there is a higher amount of palmitic acid (PA) in RBO group compared to placebo group. In Lam&#x02019;s study,<sup>(<xref ref-type="bibr" rid="B10">10</xref>)</sup> they demonstrated that PA would induce insulin resistance in L6 skeletal myotubes via inflammatory (nuclear factor kappa B/mTOR) and nutrient (ceramide) pathways. In Han&#x02019;s study,<sup>(<xref ref-type="bibr" rid="B11">11</xref>)</sup> they mentioned that PA would induce insulin resistance in L6 skeletal myotubes through C-Jun N-terminal kinase (JNK) and insulin receptor substrate-1 (IRS-1) Ser307 phosphorylation. In Yang&#x02019;s study,<sup>(<xref ref-type="bibr" rid="B12">12</xref>)</sup> they examined the antidiabetic effect of palmitoleic acid and PA in KK-A<sup>y</sup> mice. They found the PA increased the plasma glucose concentration and decreased the insulin sensitivity by up-regulated mRNA expressions of proinflammatory adipocytokine genes (TNF&#x003b1; and resistin) in white adipose compared to palmitoleic acid. So we think a higher amount of PA in RBO could not improve insulin sensitivity in our type 2 DM patients and may result in a significantly increasing of fasting and two hour postprandial blood glucose. Second, we found more MUFA exists in the RBO group compared to placebo group. In Chou&#x02019;s study,<sup>(<xref ref-type="bibr" rid="B13">13</xref>)</sup> they found that type 2 DM rats fed the RBO diet had a suppressed hyperinsulinemic response that may have resulted from the higher MUFA dietary intake. This is also may be the reason why the AUC for insulin at 5 week did not increase significantly than that at 0 week in RBO group and a significantly increasing of fasting and two hour postprandial blood glucose were observed in the RBO group compared to the placebo group in our study.</p><p>Many studies have indicated that the effective control of LDL-C in patients with type 2 diabetes is far more important than the control of HDL-C, TG, or blood glucose.<sup>(<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>)</sup> LDL, which has smaller particles and a higher particle density, is easily oxidized into oxidized-LDL (ox-LDL); ox-LDL easily enters the vascular wall and causes less release of nitric oxide (NO) and endothelial cell function impairment, attracting more monocytes to adhere to the vascular endothelium and eventually leads to atherosclerosis.<sup>(<xref ref-type="bibr" rid="B16">16</xref>)</sup> According to the National Cholesterol Education Program Adult Treatment Panel III, diabetes and cardiovascular disease are considered to be equally dangerous diseases, and the major target of treatment is LDL-C&#x02014;the goal being a concentration &#x02a7d;100&#x000a0;mg/dL.</p><p>Insulin can regulate the gene expression of LDL receptors.<sup>(<xref ref-type="bibr" rid="B17">17</xref>)</sup> Previous studies observed that LDL clearance in diabetic patients with insulin resistance is low and that LDL particles are smaller and have a higher density.<sup>(<xref ref-type="bibr" rid="B18">18</xref>)</sup> Another study indicated that blood LDL-C concentrations in type 2 diabetes patients are elevated and that insulin resistance and LDL-C concentrations are positively correlated.<sup>(<xref ref-type="bibr" rid="B19">19</xref>)</sup> Rivellese <italic>et al.</italic><sup>(<xref ref-type="bibr" rid="B20">20</xref>)</sup> indicated that a higher HOMA-IR value indicates a higher LDL concentration. The results of the present study indicate that the consumption of soybean oil&#x02013;modified milk for 5 weeks significantly increased serum LDL-C concentrations, which may have been due to an increase in insulin resistance.</p><p>Many studies have shown that RBO consumption can reduce blood cholesterol concentrations. A 10-week dietary intervention with RBO significantly reduced total plasma cholesterol concentrations in hypercholesterolemic hamsters.<sup>(<xref ref-type="bibr" rid="B21">21</xref>)</sup> Clinically, consumption of 50&#x000a0;g RBO daily for 4 weeks by hypercholesterolemia male subjects can significantly decrease total serum cholesterol concentrations,<sup>(<xref ref-type="bibr" rid="B22">22</xref>)</sup> and consumption of 75&#x000a0;mL RBO daily for 50 d by healthy subjects can reduce total serum cholesterol concentrations.<sup>(<xref ref-type="bibr" rid="B7">7</xref>)</sup> Moreover, total plasma cholesterol concentrations were significantly lower in hyperlipidemic patients who used RBO as cooking oil for 3 month than in those who used sunflower oil as cooking oil for 3 month.<sup>(<xref ref-type="bibr" rid="B8">8</xref>)</sup> Madigan <italic>et al.</italic><sup>(<xref ref-type="bibr" rid="B23">23</xref>)</sup> showed that total plasma cholesterol concentrations were significantly lower in patients with type 2 diabetes who consumed 30&#x000a0;mL olive oil and abundant oleic acid for 2 weeks than in those who consumed 30&#x000a0;mL sunflower oil and abundant linolenic acid. The results of the present study showed that total serum cholesterol concentrations decreased significantly in patients with diabetes after a 5-week dietary intervention with RBO-modified milk. This result is consistent with the results of previous studies and supports the recommendation of the American Diabetes Association that patients with type 2 diabetes should consume vegetable oil containing abundant amounts of oleic acid to improve abnormal blood lipid concentrations.<sup>(<xref ref-type="bibr" rid="B1">1</xref>)</sup></p><p>In conclusion, the 5-week dietary intervention involving consumption of 18&#x000a0;g RBO daily significantly decreased total serum cholesterol concentrations and tended to decrease LDL-C concentrations. This result is consistent with the results of previous studies and supports the recommendation of the American Diabetes Association that patients with type 2 diabetes should consume vegetable oil to improve abnormal blood lipid concentrations. However, insulin resistance was not significantly influenced.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AUC</term><def><p>area under curve</p></def></def-item><def-item><term>HbA<sub>1c</sub></term><def><p>glycosylated hemoglobin A<sub>1c</sub></p></def></def-item><def-item><term>HDL</term><def><p>high-density-lipoprotein</p></def></def-item><def-item><term>HOMA-IR</term><def><p>homeostasis model assessment index of insulin resistance</p></def></def-item><def-item><term>LDL</term><def><p>low-density-lipoprotein</p></def></def-item><def-item><term>NO</term><def><p>nitric oxide</p></def></def-item><def-item><term>OGTT</term><def><p>oral-glucose-tolerance test</p></def></def-item><def-item><term>RBO</term><def><p>rice bran oil</p></def></def-item><def-item><term>TG</term><def><p>triglyceride</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanley</surname><given-names>AJ</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Stern</surname><given-names>MP</given-names></name><name><surname>Haffner</surname><given-names>SM</given-names></name></person-group><article-title>Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>1177</fpage><lpage>1184</lpage><pub-id pub-id-type="pmid">12087016</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keys</surname><given-names>A</given-names></name></person-group><article-title>Serum cholesterol response to dietary cholesterol</article-title><source>Am J Clin Nutr</source><year>1986</year><volume>44</volume><fpage>309</fpage><pub-id pub-id-type="pmid">3728368</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franz</surname><given-names>MJ</given-names></name><name><surname>Bantle</surname><given-names>JP</given-names></name><name><surname>Beebe</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>148</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">11772915</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugano</surname><given-names>M</given-names></name><name><surname>Tsuji</surname><given-names>E</given-names></name></person-group><article-title>Rice bran oil and cholesterol metabolism</article-title><source>J Nutr</source><year>1999</year><volume>127</volume><fpage>521S</fpage><lpage>524S</lpage><pub-id pub-id-type="pmid">9082039</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunnicutt</surname><given-names>JW</given-names></name><name><surname>Hardy</surname><given-names>RW</given-names></name><name><surname>Williford</surname><given-names>J</given-names></name><name><surname>McDonald</surname><given-names>JM</given-names></name></person-group><article-title>Saturated fatty acid-induced insulin resistance in rat adipocytes</article-title><source>Diabetes</source><year>1994</year><volume>43</volume><fpage>540</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">8138059</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CW</given-names></name><name><surname>Cheng</surname><given-names>HH</given-names></name></person-group><article-title>A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes</article-title><source>J Nutr</source><year>2006</year><volume>136</volume><fpage>1472</fpage><lpage>1476</lpage><pub-id pub-id-type="pmid">16702306</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajnarayana</surname><given-names>K</given-names></name><name><surname>Prabhakar</surname><given-names>MC</given-names></name><name><surname>Krishna</surname><given-names>DR</given-names></name></person-group><article-title>Influence of rice bran oil on serum lipid peroxides and lipids in human subjects</article-title><source>Indian J Physiol Pharmacol</source><year>2001</year><volume>45</volume><fpage>442</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">11883150</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuriyan</surname><given-names>R</given-names></name><name><surname>Gopinath</surname><given-names>N</given-names></name><name><surname>Vaz</surname><given-names>M</given-names></name><name><surname>Kurpad</surname><given-names>AV</given-names></name></person-group><article-title>Use of rice bran oil in patients with hyperlipidaemia</article-title><source>Natl Med J India</source><year>2005</year><volume>18</volume><fpage>292</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">16483027</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JP</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><name><surname>Naylor</surname><given-names>BA</given-names></name><name><surname>Treacher</surname><given-names>DF</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name></person-group><article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title><source>Diabetologia</source><year>1985</year><volume>28</volume><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">3899825</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>YY</given-names></name><name><surname>Hatzinikolas</surname><given-names>G</given-names></name><name><surname>Weir</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Insulin-stimulated glucose uptake and pathways regulating energy metabolism in skeletal muscle cells: the effects of subcutaneous and visceral fat, and long-chain saturated, n-3 and n-6 polyunsaturated fatty acids</article-title><source>Biochem Biophys Acta</source><year>2011</year><volume>1811</volume><fpage>468</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">21570480</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>MS</given-names></name><name><surname>Lim</surname><given-names>YM</given-names></name><name><surname>Quan</surname><given-names>W</given-names></name><etal/></person-group><article-title>Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance</article-title><source>J Lipid Res</source><year>2011</year><volume>52</volume><fpage>1234</fpage><lpage>1246</lpage><pub-id pub-id-type="pmid">21447485</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZH</given-names></name><name><surname>Miyahara</surname><given-names>H</given-names></name><name><surname>Hatanaka</surname><given-names>A</given-names></name></person-group><article-title>Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-A<sup>y</sup> mice with genetic type 2 diabetes</article-title><source>Lipids Health Dis</source><year>2011</year><volume>10</volume><fpage>120</fpage><pub-id pub-id-type="pmid">21774832</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>TW</given-names></name><name><surname>Ma</surname><given-names>CY</given-names></name><name><surname>Cheng</surname><given-names>HH</given-names></name><name><surname>Chen</surname><given-names>YY</given-names></name><name><surname>Lai</surname><given-names>MH</given-names></name></person-group><article-title>A rice bran oil diet improves lipid abnormalities and suppress hyperinsulinemic responses in rats with streptozotocin/nicotinamide-induced type 2 diabetes</article-title><source>J Clin Biochem Nutr</source><year>2009</year><volume>45</volume><fpage>29</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">19590704</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>RB</given-names></name><name><surname>Mellies</surname><given-names>MJ</given-names></name><name><surname>Sacks</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators</article-title><source>Circulation</source><year>1998</year><volume>98</volume><fpage>2513</fpage><lpage>2519</lpage><pub-id pub-id-type="pmid">9843456</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>RC</given-names></name><name><surname>Millns</surname><given-names>H</given-names></name><name><surname>Neil</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)</article-title><source>BMJ</source><year>1998</year><volume>316</volume><fpage>823</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">9549452</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobbs</surname><given-names>FD</given-names></name></person-group><article-title>Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control</article-title><source>Int J Cardiol</source><year>2006</year><volume>110</volume><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">16289373</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streicher</surname><given-names>R</given-names></name><name><surname>Kotzka</surname><given-names>J</given-names></name><name><surname>M&#x000fc;ller-Wieland</surname><given-names>D</given-names></name><etal/></person-group><article-title>SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>7128</fpage><lpage>7133</lpage><pub-id pub-id-type="pmid">8636148</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kissebah</surname><given-names>AH</given-names></name></person-group><article-title>Low density lipoprotein metabolism in non-insulin-dependent diabetes mellitus</article-title><source>Diabetes Metab Rev</source><year>1987</year><volume>3</volume><fpage>619</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">3301236</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garvey</surname><given-names>WT</given-names></name><name><surname>Kwon</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>453</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">12540621</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivellese</surname><given-names>AA</given-names></name><name><surname>Patti</surname><given-names>L</given-names></name><name><surname>Kaufman</surname><given-names>D</given-names></name><etal/></person-group><article-title>Lipoprotein particle distribution and size, insulin resistance, and metabolic syndrome in Alaska Eskimos: the GOCADAN study</article-title><source>Atherosclerosis</source><year>2008</year><volume>200</volume><fpage>350</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">18378240</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>TA</given-names></name><name><surname>Nicolosi</surname><given-names>RJ</given-names></name><name><surname>Woolfrey</surname><given-names>B</given-names></name><name><surname>Kritchevsky</surname><given-names>D</given-names></name></person-group><article-title>Rice bran oil and oryzanol reduce plasma lipid and lipoprotein cholesterol concentrations and aortic cholesterol ester accumulation to a greater extent than ferulic acid in hypercholesterolemic hamsters</article-title><source>J Nutr Biochem</source><year>2007</year><volume>18</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">16713234</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Rein</surname><given-names>D</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Similar cholesterol-lowering properties of rice bran oil, with varied gamma-oryzanol, in mildly hypercholesterolemic men</article-title><source>Eur J Nutr</source><year>2005</year><volume>44</volume><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">15309429</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madigan</surname><given-names>C</given-names></name><name><surname>Ryan</surname><given-names>M</given-names></name><name><surname>Owens</surname><given-names>D</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Tomkin</surname><given-names>GH</given-names></name></person-group><article-title>Dietary unsaturated fatty acids in type 2 diabetes: higher levels of postprandial lipoprotein on a linoleic acid-rich sunflower oil diet compared with an oleic acid-rich olive oil diet</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><fpage>1472</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">11023139</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig.&#x000a0;1</label><caption><p>Mean effect of intervention periods on postprandial plasma glucose areas under curves (AUC) response. Values with asterisk (*) are significantly different from baseline values. Values are expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM.</p></caption><graphic xlink:href="jcbn11-87f01"/></fig><fig id="F2" position="float"><label>Fig.&#x000a0;2</label><caption><p>Mean effect of intervention periods on postprandial serum insulin areas under curves (AUC) response. Values with asterisk (*) are significantly different from baseline values. Values are expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM.</p></caption><graphic xlink:href="jcbn11-87f02"/></fig><table-wrap id="T1" position="float"><label>Table&#x000a0;1</label><caption><p>Percentage of fatty acids composition in modified milk<sup>1</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Fatty acids %</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">RBO</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">C14:0</td><td align="center" rowspan="1" colspan="1">0.1&#x000a0;&#x000b1;&#x000a0;0.0</td><td align="center" rowspan="1" colspan="1">0.4&#x000a0;&#x000b1;&#x000a0;0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">C16:0</td><td align="center" rowspan="1" colspan="1">13.5&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="center" rowspan="1" colspan="1">19.4&#x000a0;&#x000b1;&#x000a0;0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">C18:0</td><td align="center" rowspan="1" colspan="1">9.3&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" rowspan="1" colspan="1">6.8&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">C20:0</td><td align="center" rowspan="1" colspan="1">0.3&#x000a0;&#x000b1;&#x000a0;0.0</td><td align="center" rowspan="1" colspan="1">0.7&#x000a0;&#x000b1;&#x000a0;0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">C22:0</td><td align="center" rowspan="1" colspan="1">0.3&#x000a0;&#x000b1;&#x000a0;0.0</td><td align="center" rowspan="1" colspan="1">0.2&#x000a0;&#x000b1;&#x000a0;0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003a3; SFA<sup>2</sup></td><td align="center" rowspan="1" colspan="1">23.6&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="center" rowspan="1" colspan="1">27.3&#x000a0;&#x000b1;&#x000a0;1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">C16:1</td><td align="center" rowspan="1" colspan="1">0.1&#x000a0;&#x000b1;&#x000a0;0.0</td><td align="center" rowspan="1" colspan="1">0.2&#x000a0;&#x000b1;&#x000a0;0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">C18:1</td><td align="center" rowspan="1" colspan="1">19.6&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" rowspan="1" colspan="1">39.7&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003a3; MUFA<sup>2</sup></td><td align="center" rowspan="1" colspan="1">19.7&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" rowspan="1" colspan="1">39.9&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">C18:2</td><td align="center" rowspan="1" colspan="1">49.4&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="center" rowspan="1" colspan="1">31.7&#x000a0;&#x000b1;&#x000a0;0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">C18:3</td><td align="center" rowspan="1" colspan="1">7.2&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="center" rowspan="1" colspan="1">1.0&#x000a0;&#x000b1;&#x000a0;0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003a3; PUFA<sup>2</sup></td><td align="center" rowspan="1" colspan="1">56.7&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="center" rowspan="1" colspan="1">32.8&#x000a0;&#x000b1;&#x000a0;0.5</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup> Values are expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM, <italic>n</italic>&#x000a0;=&#x000a0;3. <sup>2</sup> SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid.</p></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table&#x000a0;2</label><caption><p>Average daily intake of energy, protein, fat and carbohydrate in 3-day dietary records in subjects during intervention periods<sup>1</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;17)<hr/></th><th rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">RBO (<italic>n</italic>&#x000a0;=&#x000a0;18)<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">baseline</th><th align="center" rowspan="1" colspan="1">week 5</th><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">baseline</th><th align="center" rowspan="1" colspan="1">week 5</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Kcal/day</td><td align="center" rowspan="1" colspan="1">1430.2&#x000a0;&#x000b1;&#x000a0;98.4</td><td align="center" rowspan="1" colspan="1">1448.1&#x000a0;&#x000b1;&#x000a0;89.2</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1402.8&#x000a0;&#x000b1;&#x000a0;90.3</td><td align="center" rowspan="1" colspan="1">1509.4&#x000a0;&#x000b1;&#x000a0;63.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein (g)</td><td align="center" rowspan="1" colspan="1">57.9&#x000a0;&#x000b1;&#x000a0;4.7</td><td align="center" rowspan="1" colspan="1">54.3&#x000a0;&#x000b1;&#x000a0;4.6</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">53.4&#x000a0;&#x000b1;&#x000a0;5.4</td><td align="center" rowspan="1" colspan="1">59.0&#x000a0;&#x000b1;&#x000a0;3.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Fat (g)</td><td align="center" rowspan="1" colspan="1">50.5&#x000a0;&#x000b1;&#x000a0;4.5</td><td align="center" rowspan="1" colspan="1">52.8&#x000a0;&#x000b1;&#x000a0;3.6</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">51.0&#x000a0;&#x000b1;&#x000a0;5.3</td><td align="center" rowspan="1" colspan="1">58.5&#x000a0;&#x000b1;&#x000a0;3.5</td></tr><tr><td align="left" rowspan="1" colspan="1">CHO (g)<sup>2</sup></td><td align="center" rowspan="1" colspan="1">187.0&#x000a0;&#x000b1;&#x000a0;20.3</td><td align="center" rowspan="1" colspan="1">191.3&#x000a0;&#x000b1;&#x000a0;13.0</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">183.3&#x000a0;&#x000b1;&#x000a0;11.8</td><td align="center" rowspan="1" colspan="1">187.3&#x000a0;&#x000b1;&#x000a0;9.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein (%E)<sup>2</sup></td><td align="center" rowspan="1" colspan="1">16.3&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="center" rowspan="1" colspan="1">14.8&#x000a0;&#x000b1;&#x000a0;0.5</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14.9&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="center" rowspan="1" colspan="1">15.7&#x000a0;&#x000b1;&#x000a0;0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Fat (%E)<sup>2</sup></td><td align="center" rowspan="1" colspan="1">32.3&#x000a0;&#x000b1;&#x000a0;2.7</td><td align="center" rowspan="1" colspan="1">32.9&#x000a0;&#x000b1;&#x000a0;1.5</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">32.2&#x000a0;&#x000b1;&#x000a0;2.0</td><td align="center" rowspan="1" colspan="1">34.6&#x000a0;&#x000b1;&#x000a0;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">CHO (%E)<sup>2</sup></td><td align="center" rowspan="1" colspan="1">51.8&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="center" rowspan="1" colspan="1">52.9&#x000a0;&#x000b1;&#x000a0;1.6</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">53.2&#x000a0;&#x000b1;&#x000a0;2.5</td><td align="center" rowspan="1" colspan="1">50.0&#x000a0;&#x000b1;&#x000a0;1.5</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup> Values are expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM. <sup>2</sup> CHO, carbohydrate; %E, % of energy.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table&#x000a0;3</label><caption><p>Blood glucose, insulin, HbA<sub>1c</sub> levels and HOMA-IR index in subjects during intervention periods<sup>1,2,<xref ref-type="bibr" rid="B3">3</xref></sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th colspan="3" align="center" rowspan="1">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;17)<hr/></th><th rowspan="1" colspan="1"/><th colspan="3" align="center" rowspan="1">RBO (<italic>n</italic>&#x000a0;=&#x000a0;18)<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">baseline</th><th align="center" rowspan="1" colspan="1">week 5</th><th align="center" rowspan="1" colspan="1">Change (%)</th><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">baseline</th><th align="center" rowspan="1" colspan="1">week 5</th><th align="center" rowspan="1" colspan="1">Change (%)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Fasting glucose (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">126.3&#x000a0;&#x000b1;&#x000a0;5.5</td><td align="center" valign="middle" rowspan="1" colspan="1">132.4&#x000a0;&#x000b1;&#x000a0;6.7</td><td align="center" valign="middle" rowspan="1" colspan="1">3.5&#x000a0;&#x000b1;&#x000a0;3.7</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">144.0&#x000a0;&#x000b1;&#x000a0;10.9</td><td align="center" valign="middle" rowspan="1" colspan="1">153.2&#x000a0;&#x000b1;&#x000a0;12.8*</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5&#x000a0;&#x000b1;&#x000a0;2.8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2&#x000a0;h glucose (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">266.1&#x000a0;&#x000b1;&#x000a0;17.8</td><td align="center" valign="middle" rowspan="1" colspan="1">275.3&#x000a0;&#x000b1;&#x000a0;17.8</td><td align="center" valign="middle" rowspan="1" colspan="1">4.4&#x000a0;&#x000b1;&#x000a0;3.5</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">268.2&#x000a0;&#x000b1;&#x000a0;23.5</td><td align="center" valign="middle" rowspan="1" colspan="1">291.8&#x000a0;&#x000b1;&#x000a0;25.9*</td><td align="center" valign="middle" rowspan="1" colspan="1">10.6&#x000a0;&#x000b1;&#x000a0;3.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Fasting insulin (&#x000b5;IU/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.4&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">7.6&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">24.1&#x000a0;&#x000b1;&#x000a0;13.1</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">8.0&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">8.3&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">10.6&#x000a0;&#x000b1;&#x000a0;9.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HOMA-IR<sup>4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1.8&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3&#x000a0;&#x000b1;&#x000a0;0.3*</td><td align="center" valign="middle" rowspan="1" colspan="1">36.3&#x000a0;&#x000b1;&#x000a0;12.3</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">2.7&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">3.2&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">20.7&#x000a0;&#x000b1;&#x000a0;11.9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HbA<sub>1c</sub> (%)<sup>4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">7.3&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">7.4&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5&#x000a0;&#x000b1;&#x000a0;1.1</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">7.8&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6&#x000a0;&#x000b1;&#x000a0;1.0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TC<sup>5</sup> (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">189.1&#x000a0;&#x000b1;&#x000a0;8.8</td><td align="center" valign="middle" rowspan="1" colspan="1">192.1&#x000a0;&#x000b1;&#x000a0;9.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6&#x000a0;&#x000b1;&#x000a0;1.6</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">184.3&#x000a0;&#x000b1;&#x000a0;5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">177.6&#x000a0;&#x000b1;&#x000a0;5.4*</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.6&#x000a0;&#x000b1;&#x000a0;1.2<sup>#</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TG<sup>5</sup> (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">151.7&#x000a0;&#x000b1;&#x000a0;32.9</td><td align="center" valign="middle" rowspan="1" colspan="1">149.1&#x000a0;&#x000b1;&#x000a0;24.0</td><td align="center" valign="middle" rowspan="1" colspan="1">22.4&#x000a0;&#x000b1;&#x000a0;18.4</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">112.4&#x000a0;&#x000b1;&#x000a0;9.2</td><td align="center" valign="middle" rowspan="1" colspan="1">130.1&#x000a0;&#x000b1;&#x000a0;11.6</td><td align="center" valign="middle" rowspan="1" colspan="1">19.6&#x000a0;&#x000b1;&#x000a0;9.1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HDL-C<sup>5</sup> (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">43.0&#x000a0;&#x000b1;&#x000a0;2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">42.7&#x000a0;&#x000b1;&#x000a0;2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3&#x000a0;&#x000b1;&#x000a0;2.5</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">43.3&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">43.4&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7&#x000a0;&#x000b1;&#x000a0;1.7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LDL-C<sup>5</sup> (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">108.4&#x000a0;&#x000b1;&#x000a0;8.9</td><td align="center" valign="middle" rowspan="1" colspan="1">113.6&#x000a0;&#x000b1;&#x000a0;8.9*</td><td align="center" valign="middle" rowspan="1" colspan="1">6.4&#x000a0;&#x000b1;&#x000a0;3.1</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">111.9&#x000a0;&#x000b1;&#x000a0;6.6</td><td align="center" valign="middle" rowspan="1" colspan="1">108.0&#x000a0;&#x000b1;&#x000a0;6.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.7&#x000a0;&#x000b1;&#x000a0;3.1<sup>#</sup></td></tr></tbody></table><table-wrap-foot><p><sup>1</sup> Values are expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM. <sup>2</sup> Values with asterisk (*) are significantly different from baseline values. <sup>3</sup> Values with sharp (<sup>#</sup>) are significantly different from placebo group. <sup>4</sup> HOMA-IR index are presented as insulin sensitivity; HbA<sub>1c</sub>, glycated hemoglobin. <sup>5</sup> TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.</p></table-wrap-foot></table-wrap></floats-group></article>